Comparative Pharmacology
Head-to-head clinical analysis: AMANTADINE HYDROCHLORIDE versus DENDRID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMANTADINE HYDROCHLORIDE versus DENDRID.
AMANTADINE HYDROCHLORIDE vs DENDRID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amantadine hydrochloride is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of the M2 ion channel of influenza A virus, preventing viral uncoating and replication. In Parkinson's disease, it increases dopamine release and inhibits dopamine reuptake, and also acts as an NMDA glutamate receptor antagonist, reducing excitotoxicity.
Dendrid (idoxuridine) is a pyrimidine nucleoside analog that inhibits viral DNA replication by incorporating into viral DNA and inhibiting thymidylate synthetase, thereby blocking DNA synthesis.
For parkinsonism/drug-induced extrapyramidal symptoms: initial 100 mg twice daily; may increase to 300-400 mg/day in divided doses if needed. For influenza A treatment/prophylaxis in adults: 200 mg once daily or 100 mg twice daily; initiate prophylaxis as early as possible and continue for at least 10 days post-exposure.
1.5 mg/kg IV every 8 hours; typical adult dose 100 mg IV every 8 hours.
None Documented
None Documented
Terminal elimination half-life: 10-14 hours in young adults; up to 34 hours in elderly (due to age-related decline in renal function); prolonged in renal impairment (up to 7 days in anuria).
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; prolonged in renal impairment
Renal: 90% unchanged drug via glomerular filtration and tubular secretion; minor fecal (<5%) and biliary elimination.
Primarily renal excretion; unchanged drug accounts for 70-90% of elimination; minor biliary/fecal excretion (<10%)
Category C
Category C
Antiviral / Antiparkinsonian
Antiviral